Turning Up the Heat on HD (subscription required)

Based on research out of Duke University, Chaperone Therapeutics is focusing on developing a class of Heat Shock Transcription Factor 1 (HSF1) activators, a mechanism complementary to that of Cytrx’s compound arimoclomol, currently in Phase II/III trials for ALS.

Click here to read more.

Share this: